Trials / Active Not Recruiting
Active Not RecruitingNCT07100938
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BGB-45035 Versus Placebo in Patients With Moderate to Severe Active Rheumatoid Arthritis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy of BGB-45035 in adults with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic disease-modifying antirheumatic drugs (bDMARDs)/targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-45035 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2025-08-21
- Primary completion
- 2026-10-18
- Completion
- 2026-10-18
- First posted
- 2025-08-03
- Last updated
- 2026-04-15
Locations
29 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07100938. Inclusion in this directory is not an endorsement.